
GNCA
Healthcare · Biotechnology & Medical Research · $5,878 market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 29, 2022 | Before the open | -0.18 | 0.00 | +100.0% |
| Jul 28, 2022 | Time not confirmed | -0.18 | 0.00 | +100.0% |
| May 5, 2022 | After the close | -0.18 | -0.22 | -22.2% |
| Mar 10, 2022 | Before the open | -0.20 | -0.19 | +5.0% |
| Oct 28, 2021 | Before the open | -0.20 | -0.05 | +75.0% |
| Jul 29, 2021 | Before the open | -0.18 | -0.06 | +66.7% |
| Apr 29, 2021 | Before the open | -0.20 | -0.17 | +15.0% |
| Feb 11, 2021 | Before the open | -0.21 | -0.23 | -9.5% |
| Oct 29, 2020 | Before the open | -0.24 | -0.08 | +66.7% |
| Jul 23, 2020 | Before the open | -0.40 | -0.39 | +2.5% |
| Apr 30, 2020 | Before the open | -0.35 | -0.46 | -31.4% |
| Feb 13, 2020 | Before the open | -0.39 | -0.34 | +12.8% |
| Oct 24, 2019 | Before the open | -0.46 |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a…
| -0.28 |
| +39.1% |
| Jul 25, 2019 | Before the open | -0.66 | -0.42 | +36.4% |
| Apr 30, 2019 | Before the open | -0.69 | -1.20 | -73.9% |
| Feb 28, 2019 | Before the open | -0.93 | 0.03 | +103.5% |
| Nov 1, 2018 | Before the open | -0.84 | -0.72 | +14.3% |
| Aug 2, 2018 | Before the open | -1.00 | -0.40 | +60.0% |
| May 10, 2018 | Before the open | -1.17 | -1.68 | -43.6% |
| Feb 15, 2018 | Before the open | -3.39 | -2.96 | +12.7% |